REVIEW



Effectiveness of exercise modalities on breast cancer patient outcomes: a systematic review and meta-analysis

Naser Yamani^{1*}, Aymen Ahmed², Mohammad Khan¹, Zachary Wilson¹, Muteia Shakoor², Syeda Fizza Qadri², Samuel Unzek¹, Marc Silver^{1†} and Farouk Mookadam^{1†}

Abstract

Background The effects of exercise in patients with breast cancer (BC), has shown some profit, but consistency and magnitude of benefit remains unclear. We aimed to conduct a meta-analysis to assess the benefits of varying types of exercises in patients with BC.

Methods Literature search was conducted across five electronic databases (MEDLINE, Web of Science, Scopus, Google Scholar and Cochrane) from 1st January 2000 through 19th January 2024. Randomized controlled trials (RCTs) assessing the impact of different types of exercise on outcomes related to fitness and quality of life (QOL) in patients with BC were considered for inclusion. Outcomes of interest included cardiorespiratory fitness (CRF), health-related quality of life (HRQOL), muscle strength, fatigue and physical function. Evaluations were reported as mean differences (MDs) with 95% confidence intervals (CIs) and pooled using random effects model. A p value < 0.05 was considered significant.

Results Thirty-one relevant articles were included in the final analysis. Exercise intervention did not significantly improved the CRF in patients with BC when compared with control according to treadmill ergometer scale (MD: 4.96; 95%CI [-2.79, 12.70]; P = 0.21), however exercise significantly improved CRF according to cycle ergometer scales (MD 2.07; 95% CI [1.03, 3.11]; P = 0.0001). Physical function was significantly improved as well in exercise group reported by 6-MWT scale (MD 80.72; 95% CI [55.67, 105.77]; P < 0.00001). However, exercise did not significantly improve muscle strength assessed using the hand grip dynamometer (MD 0.55; 95% CI [-1.61, 2.71]; P = 0.62), and fatigue assessed using the MFI-20 (MD -0.09; 95% CI [-5.92, 5.74]; P = 0.98) and Revised Piper scales (MD -0.26; 95% CI [-1.06, 0.55] P = 0.53). Interestingly, exercise was found to improve HRQOL when assessed using the FACT-B scale (MD 8.57; 95% CI [4.53, 12.61]; P = 0.25).

Conclusion Overall exercise significantly improves the HRQOL, CRF and physical function in patients with BC. HRQOL was improved with all exercise types but the effects on CRF vary with cycle versus treadmill ergometer. Exercise failed

[†]Marc Silver and Farouk Mookadam are co-senior authors.

*Correspondence: Naser Yamani naser.yamani2@bannerhealth.com

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicate of the version in a recedit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeccommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativeccommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

to improve fatigue-related symptoms and muscle strength. Large RCTs are required to evaluate the effects of exercise in patients with BC in more detail.

Keywords Breast neoplasm, Physical activity, Health-related quality of life, Muscle strength, Fatique, Physical function

Introduction

Breast cancer (BC) is one of the most prevalent cancers globally. Approximately 2.3 million people were diagnosed with BC in 2020, and this number is expected to rise by 40% in 2040, with the younger demographic being increasingly affected [1]. Around 685,000 patients with BC died in 2020, and the mortality burden associated with BC remains concerning due to delayed diagnoses, treatment and later stages of the disease at presentation [1]. Numerous strategies have been developed for the prevention and treatment of BC, with regular exercise being one of the most crucial components. According to the American College of Sports Medicine (ACSM) guidelines, performing at least 30 min of daily physical activity contributes to decreased likelihood of developing BC [2]. As for the patients with BC, ACSM has recommended 150 min of aerobic activity and resistance training for two or more days per week [3]. However, these patients suffer from detrimental health effects and excessive fatigue during and following cancer treatment which greatly impairs their physical functioning, reduces cardiorespiratory fitness (CRF) and muscle strength, ultimately resulting in a poor health-related quality of life (HRQOL) [4, 5]. In order to alleviate these symptoms, patients tend to rest and reduce their level of physical activity.

In 2017, Dickinson et al. [6] found that indulging in daily exercise aids in counteracting the muscular degeneration and dysfunction induced by doxorubicin (DOX) which is among the most effective drugs for treating BC. Numerous other trials and articles have also indicated that exercise is associated with improved symptoms of cancer treatment, leading to a better quality of life (QOL). However, current literature harbors conflicting results with respect to exercise intervention in patients with BC during and after treatment [7]. Although a meta-analysis by McNeelyet al. [8] in 2006 reported that exercise improved QOL, peak oxygen consumption and physical functioning, and reduced fatigue symptoms in patients with BC. Since that time however a large number of trials that have been published, that may temper the earlier results from McNeely et al. Recent meta-analyses conducted on similar topics suffer from poor quality of data assessment and outcome processing. For instance, a meta-analysis published by Furmaniak et al. in 2016 [9], emphasized that exercise is a crucial factor in eradicating the adverse effects of cancer treatment, but they reported data by merging different outcomes together and assessed it with different scales which may have led to some bias in their results.

Given the potential variations in prior studies and the absence of a recent comprehensive analysis summarizing trial-based evidence, we aimed to assess the impacts of various exercise modalities (aerobic, resistance or both combined) on QOL and health-based parameters in patients with BC during and after treatment.

Materials and methods

This systematic review and meta-analysis has been reported in accordance with guidelines provided by preferred reporting items for systematic review and meta-analyses (PRISMA) [10]. The protocol for this meta-analysis has been registered on PROSPERO and can be accessed at www.crd.york.ac.uk/PROSPERO/dis-play_record.asp?ID=CRD42024525640. Approval from the institutional review board was not required since the data was publicly available.


Data sources and search strategy

A comprehensive search was conducted across MED-LINE, Web of Science, Scopus, Google Scholar and Cochrane databases to search for randomized controlled trials (RCTs) assessing the effects of different types of exercises on post-treatment cancer outcomes in patients with BC from 1st January 2000 to 19th January 2024, without any language restrictions. The search was carried out by using the words "breast cancer", or any synonym including "breast cancer survivors". In addition, exercise was searched using the words "physical activity", "physical training." To enhance the search, Boolean operators (AND, OR) were applied. The detailed search strategy for each database is provided in Supplementary Table 1.

Study selection and data extraction

All articles retrieved from the systematic search were exported to EndNote Reference Manager (Version X7.5; Clarivate Analytics, Philadelphia, Pennsylvania) where duplicates were sought and removed. The remaining articles were assessed at title and abstract level by two independent investigators (SFQ and MS), after which full text were read to confirm relevance. Any disagreements were resolved by discussion with a third investigator (AA).

The following pre-defined inclusion criteria was used: (a) RCTs which investigated the effects of exercise on health-related outcomes in patients with BC during treatment and post-treatment, regardless of their gender and grade of cancer, (b) Exercises involving aerobic, resistance, or a combination of both involving body stretching, use of treadmill or cycle ergometer, except any aquatic exercises. (c)compared the exercise group of patients with those who had undergone usual/standard care (control group), (d) had a minimum follow-up of one month.



Data extraction and outcomes of interest

Data extraction was done by the authors SFO and MS on a pre-specified data extraction sheet. Data extracted from the studies included the publication year, sample size, mean age of the intervention and the control group, the intervention provided, duration, intensity and frequency of the intervention, number of patients in the control and the intervention group and the scales used for assessing the outcomes. Outcomes of interest were patient-reported improved CRF, fatigue, physical function, muscle strength and hence the overall improvement in the OOL. Each outcome was measured with certain scales, HRQOL (Functional Assessment of Cancer Therapy-Breast; FACT-B and European Organization for the Research and Treatment of Cancer Quality of Life; EORTIC QLQ-C30), Fatigue (Multidimensional Fatigue Inventory; MFI-20 and Revised Piper Fatigue scale), Physical function (6 min Walking Test; 6-MWT), CRF (peak oxygen uptake in ml/kg/min by treadmill and cycle ergometer) and Muscle strength by hand grip dynamometer.

Statistical analysis

The software used for analysis is Review Manager (Version 5.4.1) [11]. Continuous variables were reported as mean differences (MDs) with corresponding 95% confidence intervals (CIs), and were pooled using a generic inverse variance random-effects model. The I² statistic was used to evaluate heterogeneity across studies, and a value of I²=25-50% was considered mild, 50-75% as moderate and I²>75% as severe [12]. A p-value<0.05 was considered statistically significant in all cases.

Risk of bias assessment

The methodological risk of bias assessment of all RCTs was evaluated according to Revised Cochrane Risk of Bias tool (Rob2) [13]. Studies were assessed based on the following domains: selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias, and were categorized in each domain on the basis of low risk (+), unclear risk (?) and high risk (-). Figure 1 shows detailed assessment of risk of bias.

Results

Literature search

The initial searching of database and registers yielded 34,849 studies. After title, abstract and duplicates screening, 73 articles were identified for full-text assessment. Further, 42 full-text articles were excluded based on issues with study design, irrelevant outcomes, no published data, and other reasons including non-availability of article in English language. Thus, 31 articles were found potentially relevant for the final analysis. The

summary of our literature search results is presented in the PRISMA flow chart (Fig. 2).

Study characteristics and risk of bias assessment

A total of 3,059 patients with BC were involved in analysis, out of which majority (85.7%) were female participants. The mean age of participants involved in exercise (intervention) and control group is 52.6 (standard deviation [SD]: 9.0) and 52.7 (SD: 8.25) respectively. The mean BMI at baseline of exercise (intervention group) and control group is 25.24 (SD: 4.43) and 25.41 (SD: 3.98) respectively. The summary of study characteristics and participants demographics are presented in Table 1. The risk of bias across the included studies was unclear (Fig. 1). Visual inspection of funnel plots suggested at least 10 studies with publication bias (Supplementary Fig. 1A, B).

Meta-analysis results

Figures 3, 4, 5, 6 and 7 display the effects of exercise on health-related outcomes in patients with BC when compared with control (usual/standard care).

CRF

Eight studies evaluated the effect of exercise on CRF. Exercise did not significantly improved the CRF assessed by treadmill ergometer (n=4) when compared with patients with BC receiving usual care (MD 4.96; 95% Cl [-2.79, 12.70]; P=0.21; I²=96%). However, exercise significantly improved the CRF assessed by cycle ergometer (n=4) compared with usual care (MD 2.07; 95% Cl [1.03–3.11]; P=0.0001; I²=0%). Particularly, aerobic exercise group significantly improved the CRF when assessed by cycle ergometer compared with usual care (MD 2.48; 95% Cl [1.11, 3.84]; P=0.0004; I²=0%) Fig. 3A, B represents the analysis results of CRF.

HRQOL

HRQOL was monitored by twenty-five studies using two scales. Exercise did not significantly improve HRQOL assessed by EORTC QLQ C-30 scale (n=13) compared with usual care. (MD 1.19; 95% Cl [-1.96, 4.34]; P=0.46; I²=86%). However, combined exercise showed significant improvements in HRQOL assessed by EORTC QLQ-C30 scale compared with patients with BC receiving usual care (MD 6.78; 95% Cl [2.40, 11.15]; P=0.002; I²=2%). In




Fig. 2 The PRISMA flow chart summarizing literature search results

Study	Study design	Sam- ple size	Participants		Mean age (m	age (mean, Sd)	Mean BMI		Patients lost to follow up	t to follow	Intervention	Duration of inter- vention	Intensity of intervention	Outcome
				Control	Intervention	Control	Intervention Control	Control	Intervention	n Control		/weeks		
Segal et al., [14]	Random- ized controlled trial	123	82		51.2 (8.7)	50.3 (8.7)			0		Supervised aerobic exercise	26 weeks	50–60% of the maximal oxy- gen uptake	HRQOL, as- sessed using FACT B scale
Drouin et al, [15]	Random- ized controlled trial	21	£	10	49.4(7.0)	51.9(10.0					Aerobic exercise	7 weeks	50–70% of maximum heart rate	Fatigue assessed by Revised Piper and CRF by treadmill ergometer
Cour- neya et al., [16]	Prospec- tive, ran- domized controlled trial	52	24	28	59 (5)	58 (6)	29.4 (7.4)	29.1 (6.1)	_	0	Aerobic exercise, cycle ergometers	15 weeks	70–75% of max- imal oxygen consumption.	HRQOL, as- sessed using FACT B scale
Batta- gliani et al., [17]	Random- ized controlled trial	20	10	10	ı	1			ı		Mixed aerobic and resistance	15 weeks	40–60% pre- dicted exercise capacity	Fatigue assessed by Revised Piper scale
Mock et al., [18]	Random- ized controlled trial	119	60	59	51.3(8.9)	51.6 (9.7)	25.5(4.0)	25.8(5.1)	Q	2	Aerobic exercise	6 weeks	50–70% of maximum heart rate	Fatigue assessed by Revised Piper scale
Anna Camp- bell et al., [19]	Random- ized controlled trial	6	12	10	48 (10)	47 (5)			ı		Mixed aerobic and resistance exercise	12 weeks	60–75% of maximum heart rate	HRQOL, as- sessed using FACT B scale
Tinna et al., [20]	Prospec- tive, non- blinded random- ized two- arm phase III trial	200	263	237	52.3 (8)	52.4 (8.25)			21	16	Aerobic exercise	52 weeks	86–92% of maximal heart rate	HRQOL, as- sessed using EORTC QLQ- C30 scale
T. Schmidt et al., [21]	Prospec- tive, ran- domized study	38	15	8	58 (8.4)	55 (10.59)			ı	I	Aerobic exercise	26 weeks		HRQOL, as- sessed using EORTC QLQ- C30 scale

Yamani et al. Cardio-Oncology

Page 5 of 16

Study	Study design	Sam- ple	Participants		Mean age (m	age (mean, Sd)	Mean BMI		Patients lost to follow up	to follow	Intervention	Duration of inter-	Intensity of intervention	Outcome
		size										vention /weeks		
			Intervention	Control	Intervention Control	Control	Intervention Control	Control	Intervention	Control				
Laura et al., [22]	Random- ized controlled trial	222	105	108	54.9 (9.3)	53.9 (7.7)			0	0	Exercise, non specified	13 weeks	40–59% of of maximum heart rate to 40–59% of of maximum heart rate	HRQOL, as- sessed using FACT B scale
Martina et al., [23]	Prospec- tive, ran- domized, controlled trial	95	49	46	52.2 (9.9)	53.3 (10.2)	25.7 (4.6)	26.3 (4.9)	m	m	Resistance exercise	12 weeks	ı	HRQOL, as- sessed using EORTC QLQ- C30 scale
Stein- dorf et al., [24]	Prospec- tive, ran- domized, controlled trial	160	80	80	55.2 (9.5)	56.4 (8.7)	26.9 (5.4)	27.6 (4.8)	m	7	Resistance exercise	12 weeks		HRQOL, as- sessed using EORTC QLQ- C30 scale
Murte- zani et al., [25]	Prospec- tive, ran- domized controlled trial	62	30	32	53 (11)	51 (11)	25.9 (2.8)	26.0 (3.3)	7	4	Aerobic exercise	10 weeks	50–75% hear rate reserve	HRQOL, as- sessed using FACT B scale
Thor- sten et al, [26]	Prospec- tive, controlled and ran- domized interven- tion trial	<u>ω</u>			56(10.15)	54(11.9)			12	7	Combined exercise.	12 weeks		HRQOL, as- sessed using EORTC QLQ- C30 scale. Fatigue assesed using MFI-20 scale.
Camp- bell et al., [27]	Random- ized controlled trial	6	10	6	53.2(7.0)	51.4(5.1) 26.3(5.7)	26.3(5.7)	26.1(5.5)	m	7	Aerobic exercise	24 weeks	From 60–80% heart rate reserve	CRF as- sesed using treadmil
Chris- tina et al., [28]	Random- ized controlled trial	100							4	2	Combined exercise	17 weeks	50 and 70% heart rate maximum	HRQOL, as- sessed using FACT B scale. CRF as- sessed using treadmil.

Table 1 (continued)

Study	Study design	Sam- ple size	Sam- Participants ple size		Mean age (m	age (mean, Sd)	Mean BMI		Patients lost to follow up	t to follow	Intervention	Duration of inter- vention	Intensity of intervention	Outcome
			Intervention	Control	Intervention Control		Intervention Control	Control	Intervention	control		/weeks		
Cešeiko et al., [29]	Random- ized controlled trial	55	27	28	48.2 (6.7)				1		Resistance exercise	12 weeks	,	HRQOL, as- sessed using EORTC QLQ- C30 scale
Northey et al., [30]	3 arm, ran- domized controlled trial	17	Q	9	60.3 (8.1)	61.5 (7.8)			0	0	Aerobic exercise	12 weeks	90% of maxi- mum heart rate	CRF assesed using cycle ergometer
Jessica et al., [31]	Parallel- group random- ized trial	174	23	57	59(9)	58(9)	30.1(6)	29.1(5.2)	E	~	Aerobic exercise	16 weeks	alternated among intensi- ties of 55%, 80%, and > 95% of maximal oxygen consumption	HRQOL, as- sessed using FACT B scale. CRF as- sessed using treadmil.
Julia et al., [32]	Random- ized controlled trial	63	31	32	51.32 (10.15) 48.33 (7.72)	48.33 (7.72)			Ŋ	4	Aerobic exercise	24 weeks	1	HRQOL, as- sessed using EORTC QLQ- C30 scale
Kyuwan et al [33]	Single- center, pilot ran- domized controlled trial	00	15	15					0	0	Aerobic exercise	8 weeks	Individu- ally prescribed based on maxi- mal oxygen consumption	HRQOL, as- sessed using FACT B scale. Fatigue as- sessed using MFI20 scale. Physical function assessed using 6MTW scale.
Sibel et al., [34]	prospec- tive, single- blind, random- ized trial	31	15	16	51.40 (10.6)	50.7 (7.6)	26.0 (4.9)	24.5(3.4)	0	0	Yoga	10 weeks		HRQOL, as- sessed using EORTC QLQ- C30 scale

Table 1 (continued)

		() ()				e u					1			
study	study design	sam- ple	sam- Participants ple		Mean age (me	age (mean, 5d)	Mean BMI		Patients lost to follow up		Intervention	Duration of inter-	Intensity of intervention	Outcome
		size	I									vention /weeks		
			Intervention	Control	Intervention Control	Control	Intervention Control	Control	Intervention Co	Control				
Jenny et al., [35]	random- ized, controlled, prospec- tive inter- ventional PhysSURG- B trial	287	139	148					57 46		Aerobic exercise	6 weeks	1	HRQOL, as- sessed using FACT B scale
Yawei et al., [36]	single- blind ran- domized parallel controlled tria	200	Aerobic=49, Resistance=47	48	aero- bic=47.37 (9.99), resis- tance=49.38 (9.51)	51.69 (10.14)	aero- bic = 22.92 (3.27), resis- tance = 23.90 (4.37)	23.90 (3.85)	9		Combined exercises	26 weeks	60–80% of the maximum heart rate	HRQOL, as- sessed using FACT B scale
Eisuke et al., [37]	parallel- group, single- blind, ran- domised controlled trial	20	21	23	48 (б)	49 (5)	21.0 (2.2)	20.9 (2.0)	9		Resistance exercise	12 weeks	1	CRF assesed using cycle ergometer
Xialon et al., [38]	single- blinded random- ized con- trolled trial	70	35	35			22.86 (2.55)	23.26 (2.56)	C M		Baduanjin exercise	12 weeks	,	HRQOL, as- sessed using FACT B scale
Kwang et al., [39]	Random- ized controlled trial	30	15	15	54.7 (5.1)	55.4 (4.3)	23.3 (3.26)	24.4 (3.34)	2 3		Resistance exercise	12 weeks	1	Muscle strength as- sessed using hand grip dyanometer
Wei- Pang et al., [40]	Random- ized controlled trial	32	16	13	52.4 (8.9)	50.3 (7.7) 24.6 (6.1)	24.6 (6.1)	23.2 (2.7)	m O		Combined exercise	13 weeks	70–75% of max- imal oxygen consumption.	CRF assesed using cycle ergometer

Study	Study design	Sam- ple size	sam- Participants ple size		wean age (mean, su)				up	10 10110W	Intervention	Duration of inter- vention /weeks	Intensity of intervention	Outcome
				Control	Intervention Control Intervention Control		Intervention Control	Control	Intervention Control	Control				
Fahimeh c et al., b [41] [41] t t	double- blinded random- ized con- trolled trial,	76	35	35 S	38.14 (10.70)	42.63 (8.11)					Aerobic exercise	5 weeks		HRQOL, as- sessed using EORTC QLQ C30 scale. Physical function assessed using 6MTW
Anna et al., [42]	non- blinded random- ized controlled	577	288	88	58 (12)	58 (11)			15	Q	Combined exercise	12 weeks	40–50% of the heart rate reserve	HRQOL, as- sessed using EORTC QLQ- C30 scale
Kristiina et al., [43]	andom- ized controlled trial	446	106	446	52(7)	53(8)	24.6(3.5)	25.9 (4.1)		ı	Aerobic exercise	52 weeks		HRQOL, as- sessed using EORTC QLQ- C30 scale.
Jung et al., [44]		60	28	29	46.9 (8.3)	48.1 (7.9)			5	-	Combined exercise	4 weeks	40% of maxi- mal oxygen consumption	HRQOL, as- sessed using EORTC QLQ- C30 scale.


Yamani et al. Cardio-Oncology (

Table 1 (continued)

(2024) 10:38

Page 9 of 16

A



В

	Ex	ercis	0	C	ontro	k		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI Y	fear	IV, Random, 95% CI
1.6.1 Aerobic exercis	5e									
Courneya et al.	21.3	3.7	24	18.2	3.9	28	25.4%	3.10 [1.03, 5.17] 2	2003	
Northey et al.	23.1	4.3	6	20.3	2.9	6	6.3%	2.80 [-1.35, 6.95] 2	019	
Subtotal (95% CI)			30			34	31.7%	3.04 [1.19, 4.89]		-
Heterogeneity: Tau ² =					= 0.9	$0); I^2 =$	0%			
Test for overall effect:	Z = 3.22	! (P =	0.001)							
1.6.2 Resistance exe	rcise									
Eisuke et al.	25.9	2.8	21	24.1	4	23	26.4%	1.80 [-0.23, 3.83] 2	022	
Subtotal (95% CI)			21			23	26.4%	1.80 [-0.23, 3.83]		
Heterogeneity: Not ap	plicable									
Test for overall effect:	Z = 1.74	(P =	0.08)							
1.6.3 Combined exer	cise									
Wei Pang et al.	13.6	2.2	16	12.1	2.2	13	41.9%	1.50 [-0.11, 3.11] 2	022	
Subtotal (95% CI)			16			13	41.9%	1.50 [-0.11, 3.11]		◆
Heterogeneity: Not ap	plicable									
Test for overall effect:	Z = 1.83	(P =	0.07)							
Total (95% CI)			67			70	100.0%	2.07 [1.03, 3.11]		•
Heterogeneity: Tau ² =	0.00; Cł	ni² = 1	.62, df	= 3 (P	= 0.6	5); l ² =	0%		+	
Test for overall effect:									-10	-5 0 5 10
Test for subgroup diffe		•		· · · · · · · · · · · · · · · · · · ·	P = 0).45), l ²	= 0%			Favours [control] Favours [exercise]

Fig. 3 A pooled results of CRF by treadmill ergometer. B Pooled results of CRF by cycle ergometer

contrast, HRQOL assessed by FACT-B scale, using direct post-intervention values (n=10), showed significant improvement in exercise group compared with usual care (MD 8.83; 95% Cl [4.71, 12.96], P<0.0001; I²=83%). However, HRQOL assessed by FACT-B scale using mean change from baseline data (n=2) showed non-significant improvements in exercise group (MD 6.74; 95% Cl [-4.42, 17.89]; P=0.24; I²=46%). (Fig. 4A, B, C)

Muscle strength

The effect of exercise on muscle strength assessed by hand grip strength was demonstrated by two studies. Both studies showed non-significant improvements in exercise group compared with patients with BC undergoing usual care. (MD 0.55; 95% Cl [-1.61, 2.71]; P=0.62; $I^2=0\%$). (Fig. 5)

Fatigue

Fatigue was monitored by six studies using two scales. MFI-20 scale (n=2) demonstrated non-significant improvements in fatigue in exercise group compared with usual care group (MD -0.09; 95% Cl [-5.92, 5.74], P=0.98; I²=47%). Fatigue assessed by Revised Piper Fatigue Scale using direct post-intervention (n=2) and mean change from baseline data (n=2) displayed non-significant improvements in the exercise group (MD -0.26; 95% Cl [-1.06, 0.55]; P=0.53; I²=0% in direct post-intervention

А

	C	ontrol		Ex	ercise			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.1.1 Aerobic exerci	se									
T. Schmidt et al.	76	12.93	15	77	15.27	18	5.7%	-1.00 [-10.62, 8.62]	2012	
Tinna et al.	4.2	1.2	263	5.6	1.3	237	12.0%	-1.40 [-1.62, -1.18]	2012	
Thorsten et al.	36.79	17.99	21	30.955	15.29	26	5.6%	5.84 [-3.85, 15.52]	2015	
Julia et al.	65.1	11.4	32	70.85	4.8	31	9.8%	-5.75 [-10.05, -1.45]	2020	
Fahimeh et al.	51.62	2.91	35	60.57	6.15	35	11.3%	-8.95 [-11.20, -6.70]	2022	-
Kristiina et al. Subtotal (95% CI)	74	19	106 472	71	19	446 793	10.0% 54.4%	3.00 [-1.02, 7.02] -2.21 [-6.27, 1.86]	2022	•
Heterogeneity: Tau ²	= 19.08;	Chi ² =	53.44,	df = 5 (P	< 0.00	001); I ²	= 91%			
Test for overall effect	t: Z = 1.0	6 (P = 6	0.29)							
1.1.2 Resistance exe										
Steindorf et al.	64	25	80	62	21	80	7.4%	2.00 [-5.15, 9.15]		
Martina et al.	61.7	18.3	49	54.9	22.9	46	6.5%	6.80 [-1.57, 15.17]		
Thorsten et al.	31.29			30.955		26	6.1%	0.34 [-8.65, 9.32]		
Cešeiko et al.	76.2	14.3	27	63.5	14.7	28	7.0%	12.70 [5.04, 20.36]	2019	
Subtotal (95% CI)		-1.2	177			180	27.0%	5.58 [0.08, 11.08]		-
Heterogeneity: Tau ²				t = 3 (P =	= 0.13);	$1^{\circ} = 47$	'%			
Test for overall effect	t: $Z = 1.9$	19 (P = 0)	0.05)							
1.1.3 Combined exe	rcise									
Anna et al.	75	19	288	67	21	89	9.3%	8.00 [3.12, 12.88]	2022	
lung et al.	65.1	18.7	28	62.4	16	29	6.0%	2.70 [-6.35, 11.75]		
Subtotal (95% CI)			316			118	15.3%	6.78 [2.40, 11.15]		•
Heterogeneity: Tau ²	= 0.28; 0	$hi^2 = 1$.02, df	= 1 (P =	0.31); 1	$^{2} = 2\%$				
Test for overall effect										
1.1.4 Yoga										
Sibel et al.	68.3	20.6	15	69.7	20.7	16	3.4%	-1.40 [-15.94, 13.14]	2021	
Subtotal (95% CI)			15			16	3.4%	-1.40 [-15.94, 13.14]		
Heterogeneity: Not a	pplicable									
Test for overall effect	t: $Z = 0.1$	9 (P =)	0.85)							
Total (95% CI)			980			1107	100.0%	1.19 [-1.96, 4.34]		L
Heterogeneity: Tau ²	= 21 53	Chi ² =		df = 12.0	P < 0.0			1.20 (1.00, 4.04)	⊢	i0 -25 0 25
	- 41.33,	- m	00.40,	ui - 12 (0.0	000I),	- 00%			
Test for overall effect	+ 7 - 0 7	A (P - 4	0.46)						-5	i0 -25 0 25 Favours [Control] Favours [Exercise]


В

Total (95% CI)

92

Heterogeneity: Tau² = 37.17; Chi² = 1.84, df = 1 (P = 0.17); l² = 46% Test for overall effect: Z = 1.18 (P = 0.24)

	Ex	ercise		C	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean		Total	Weight		Year	IV. Random, 95% Cl
1.4.1 Aerobic exercis	e									
Courneva et al.	119.6	16.9	24	115.8	14.9	28	8.2%	3.80 [-4.93, 12.53]	2003	
vlurtezani et al.	113.2	9.7	30	101.2	9.5	32	11.1%	12.00 [7.22, 16.78]		
aura et al.	115.9	17.2	110	109.4	20.4	112	10.9%	6.50 [1.54, 11.46]		_ _
lessica et al.	107.8	20.7	58	108.9	16.2	57	9.6%	-1.10 [-7.89, 5.69]	2020	_ _
yuwan et al.	85.4	20.4	15	66.1	22.4	15	4.6%	19.30 [3.97, 34.63]	2021	
aweietal.	113.59	17.38	144	101.79	15.54	48	10.7%	11.80 [6.57, 17.03]	2022	
enny et al. ubtotal (95% Cl)	116.3	20	139 520	117	18.2	148 440		-0.70 [-5.13, 3.73] 6.49 [1.58, 11.40]	2022	◆
leterogeneity: Tau² =	31.60; CI	ni² = 26.	.90, df=	6 (P = 0	.0002);	I ² = 78	%			
est for overall effect:	Z = 2.59 (P = 0.0	10)							
.4.2 Resistance exe										
awei et al. Jubtotal (95% CI)	119.17	13.75	144 144	101.79	15.54	48 48	10.9% 10.9 %	17.38 [12.44, 22.32] 17.38 [12.44, 22.32]	2022	•
leterogeneity: Not ap est for overall effect:		P < 0.0	0001)							
4.3 Combined exer	cise									
hristina et al. Ubtotal (95% CI)	113	13	46 46	96.3	14.5	45 45		16.70 [11.04, 22.36] 16.70 [11.04, 22.36]	2018	→
leterogeneity: Not ap 'est for overall effect:		P < 0.0	0001)							
.4.4 Baduanjin exerc	cise									
ïaolin et al.	113.26	6.25	35	106.17	6.72	35	12.1%	7.09 [4.05, 10.13]	2022	
ubtotal (95% CI)			35			35	12.1%	7.09 [4.05, 10.13]		◆
leterogeneity: Not ap est for overall effect:		P < 0.0	0001)							
otal (95% CI)			745			568	100.0%	8.83 [4.71, 12.96]		•
eterogeneity: Tau² =	34.14; CI	ni² = 52.	.76, df=	9 (P < 0	.00001); l ² = 8	3%			-20 -10 0 10 20
est for overall effect:										-20 -10 Ó 10 20 Favours (control) Favours (exercise)
est for subgroup diff	erences:	Chi ^z = 1	9.40, d	f= 3 (P =	0.0002	2), I² = 8	34.5%			
		xercis	0	C	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mea			Mean		Total	Woinht	IV, Random, 95% Cl	Vear	IV, Random, 95% Cl
		7 17.3			12.5					IV, Kalluolli, 55% Cl
Segal et al.						41 9	72.6%	3.24 [-2.11, 8.59]	2001	
Anna Campbell et a	1. 14.	3 19.8	10	-1.7	19.4	Э	21.4%	16.00 [-1.64, 33.64]	2005	



50 100.0% 6.74 [-4.42, 17.89]

-50 -25 0 25 50 Favours [control] Favours [exercise]

		ventio	-		ontro			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD T	otal I	/lean	SD	Tota	l Weigł	it IV, Random, 95%	CI Year	IV, Random, 95% Cl
1.1.1 Aerobic exerci	ise									
Drouin et al. Subtotal (95% CI)	31.3	6.5	13 13	32	6.4	10 10		% -0.70 [-6.01, 4.6 % - 0.70 [-6.01, 4.6		
Heterogeneity: Not a Test for overall effect		6 (P = 0	0.80)							
1.1.2 Resistance exe	ercise									
Kwang et al. Subtotal (95% CI)	25	3.1	15 15	24.2	3.5	15 15				
Heterogeneity: Not a Test for overall effect	••	6 (P = 0	0.51)							
Total (95% CI)			28			25	5 100.0	% 0.55 [-1.61, 2.7	11	
Heterogeneity: Tau ²	- 0 00· C	$hi^2 = 0$		_ 1 (D _				-1	
Test for overall effect			,,	- 1 ()	г —	0.01),	-0/0			-20 -10 0 10
			0 (2)							
Test for subgroup di				df = 1	1 (P	= 0.61), $I^2 = 0$	6		Favours [Control] Favours [Exercise]
Test for subgroup di	fferences	Chi ² =	0.26,		-			6		
Test for subgroup dir g. 5 Pooled results f	fferences: from mus	Chi ² =	0.26,	by har	nd g					Favours [Control] Favours [Exercise]
Test for subgroup dii g.5 Pooled results f	fferences: from mus Interve	Chi ² = cle stre	0.26, ength k	by har Cont	nd g trol	rip stre	ength	Mean Difference	Year	Favours [Control] Favours [Exercise] Mean Difference
Test for subgroup di g. 5 Pooled results f A Study or Subgroup	fferences: from mus Interve Mean	Chi ² = cle streention SD To	ength k	oy har Cont an	nd g trol SD	jrip stre Total	ength Weight	Mean Difference IV, Random, 95% Cl		Favours [Control] Favours [Exercise]
Test for subgroup dii g. 5 Pooled results f A <u>Study or Subgroup</u> Thorsten et al.	fferences: from mus Interve <u>Mean</u> 10.55 3	Chi ² = cle streention <u>SD To</u> .22	0.26 , ength k tal Me 21 12.	Cont an 38	nd g trol <u>SD</u> 3.5	prip stre Total 26	ength <u>Weight</u> 74.5%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2	2015	Favours [Control] Favours [Exercise] Mean Difference
Test for subgroup di g. 5 Pooled results f A Study or Subgroup	fferences: from mus Interve Mean	Chi ² = cle streention <u>SD To</u> .22	0.26 , ength k tal Me 21 12.	oy har Cont an	nd g trol <u>SD</u> 3.5	jrip stre Total	ength <u>Weight</u> 74.5%	Mean Difference IV, Random, 95% Cl	2015	Favours [Control] Favours [Exercise] Mean Difference
Test for subgroup dii g. 5 Pooled results f A <u>Study or Subgroup</u> Thorsten et al.	fferences: from mus Interve <u>Mean</u> 10.55 3	Chi ² = cle stree ention <u>SD To</u> .22 4.1	0.26 , ength k tal Me 21 12.	Cont an 38	nd g trol <u>SD</u> 3.5	rip stre Total 26 15	ength Weight 74.5% 25.5%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2	2015	Favours [Control] Favours [Exercise] Mean Difference
Test for subgroup dii g. 5 Pooled results f A Study or Subgroup Thorsten et al. Kyuwan et al. Total (95% Cl) Heterogeneity: Tau ² =	fferences: from mus Interve <u>Mean</u> 10.55 3 54.3 1 = 10.92; Cł	Chi ² = cle stree ention SD To .22 4.1 hi ² = 1.8	0.26, ength b tal Me 21 12. 15 49 36 38, df =	Cont an 38 3 9.3 12	nd g trol <u>SD</u> 3.5 2.6	rip stre <u>Total</u> 26 15 41	Weight 74.5% 25.5% 100.0%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2 5.00 [-4.57, 14.57] 2	2015	Favours [Control] Favours [Exercise] Mean Difference IV, Random, 95% Cl
Test for subgroup dii g. 5 Pooled results f A <u>Study or Subgroup</u> Thorsten et al. Kyuwan et al. Total (95% CI)	fferences: from mus Interve <u>Mean</u> 10.55 3 54.3 1 = 10.92; Cł	Chi ² = cle stree ention SD To .22 4.1 hi ² = 1.8	0.26, ength b tal Me 21 12. 15 49 36 38, df =	Cont an 38 3 9.3 12	nd g trol <u>SD</u> 3.5 2.6	rip stre <u>Total</u> 26 15 41	Weight 74.5% 25.5% 100.0%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2 5.00 [-4.57, 14.57] 2	2015	Favours [Control] Favours [Exercise]
Test for subgroup di g. 5 Pooled results f A Study or Subgroup Thorsten et al. Kyuwan et al. Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:	fferences: from mus Interve <u>Mean</u> 10.55 3 54.3 1 = 10.92; Cł	Chi ² = cle stree ention SD To .22 4.1 hi ² = 1.8	0.26, ength b tal Me 21 12. 15 49 36 38, df =	Cont an 38 3 9.3 12	nd g trol <u>SD</u> 3.5 2.6	rip stre <u>Total</u> 26 15 41	Weight 74.5% 25.5% 100.0%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2 5.00 [-4.57, 14.57] 2	2015	Favours [Control] Favours [Exercise] Mean Difference IV, Random, 95% Cl
Test for subgroup dii g. 5 Pooled results f A Study or Subgroup Thorsten et al. Kyuwan et al. Total (95% Cl) Heterogeneity: Tau ² =	fferences: from mus not start from mus not start from mus not start from mus from mus from mus from mus from mus from mus not start from mus not start from mus not start from mus not start from mus from	Chi2 = cle streetcle streetsolutionSD To.224.1hi2 = 1.8(P = 0.9	tal Me tal Me 21 12. 15 49 36 38, df =	Cont an 38 3 9.3 12 1 (P =	nd g trol <u>SD</u> 3.5 2.6 = 0.1	rip stre <u>Total</u> 26 15 41	weight 74.5% 25.5% 100.0% 47%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2 5.00 [-4.57, 14.57] 2 -0.09 [-5.92, 5.74]	2015	Favours [Control] Favours [Exercise] Mean Difference IV, Random, 95% CI -20 -10 0 10 20 Favours [Control] Favours [Exercise]
Test for subgroup di g. 5 Pooled results f A Study or Subgroup Thorsten et al. Kyuwan et al. Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:	fferences: from mus Interve Mean 10.55 3 54.3 1 = 10.92; Cf: : Z = 0.03	Chi ² = cle stree stree SD To .22 4.1 $hi^2 = 1.8$ (P = 0.9 cise	tal Me tal Me 21 12. 15 49 36 38, df = 28)	Cont an 38 38 1 (P = Cont	nd g trol <u>SD</u> 3.5 2.6 = 0.1	Total 26 15 41 17); 1 ² =	ength 74.5% 25.5% 100.0% 47%	Mean Difference IV, Random, 95% CI -1.83 [-3.76, 0.10] 2 5.00 [-4.57, 14.57] 2	2015 2021	Favours [Control] Favours [Exercise]

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI Year		IV,	Rando	m, 95% C	1	
Drouin et al.	3.4	1.9	13	3.9	2.4	10	19.8%	-0.50 [-2.31, 1.31] 2002			-			
Mock et al.	3.5	2.4	60	3.7	2.6	59	80.2%	-0.20 [-1.10, 0.70] 2005			-	_		
Total (95% CI)			73			69	100.0%	-0.26 [-1.06, 0.55]			-	•		
Heterogeneity: Tau ² = Test for overall effect:				f = 1 (P	= 0.7	7); ² =	0%		-4	-2 Favours [co	0 ontrol]	Favours	2 [exercise]	4

С

	Ex	ercise	9	Co	ontro	1		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
Anna Campbell et al.	2.11	2.3	10	0.25	2.5	9	23.2%	1.86 [-0.31, 4.03]	2005	
Battagliani et al.	-0.15	0.88	10	-0.66	1.3	10	76.8%	0.51 [-0.46, 1.48]	2007	
Total (95% CI)			20			19	100.0%	0.82 [-0.29, 1.94]		•
Heterogeneity: Tau² = ().18; Chi	z =1.2	4, df=	1 (P = 0	.27);	l ^z = 199	6		-	
Test for overall effect: Z	(= 1.44	P = 0.1	15)							Favours (control) Favours (exercise)

Fig. 6 A Pooled results from Fatigue by MFI-20. B Pooled results from Fatigue by Revised Piper Fatigue scale (Direct post-intervention data). C Pooled results, Fatigue by Revised Piper Fatigue scale (Mean change from baseline data)

	Ex	ercise		C	ontrol			Mean Difference			Mean Di	ference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year		IV, Rando	m, 95% Cl	
Kyuwan et al.	490.8	63.34	15	430.23	86.46	15	21.3%	60.57 [6.33, 114.81]	2021				
Fahimeh et al.	385.49	42.69	35	299.31	73.79	35	78.7%	86.18 [57.94, 114.42]	2022				
Total (95% CI)			50			50	100.0%	80.72 [55.67, 105.77]				•	
Heterogeneity: Tau ² = Test for overall effect:				(P = 0.41	1); I² = 0	%				-200	-100 (Favours (control)) 100 Favours (exercis	200 e]

Fig. 7 Pooled results from physical function by 6 MWT

data and MD 0.82; 95%Cl [-0.29, 1.94]; *P*=0.15; I²=19% in mean change from baseline data). (Fig. 6A, B, C)

Physical function

Physical function (n=2) assessed by 6 MWT was significantly improved in the exercise group compared with the usual care group (MD 80.72; 95% Cl [55.67, 105.77]; P<0.00001; I²=0%). (Fig. 7)

Discussion

Our updated meta-analysis including over 3000 patients with BC outlines several key findings. First, exercise in patients with BC leads to significantly improved CRF. Second, exercise improved the HRQOL in patients with BC during and after treatment. Third, physical functioning was greatly improved in patients undergoing exercise. Lastly, the results of our meta-analysis indicate, combined exercise regimen including both aerobic and resistance training is more effective for improvement of health-related outcomes in patients with BC.

Our findings concur with prior meta-analyses evaluating the effects of exercise in patients with BC. However, the multiple short-comings of previous meta-analyses confer greater reliability to our results. Although prior meta-analyses and reviews have shown that exercise improves health-related outcomes including CRF, HRQOL and physical function in patients with BC [8, 9], they have often pooled different types of exercise like resistance training, strength training, yoga and aerobic exercise like treadmill and cycling were pooled together. Such analyses may lack accuracy and reliability owing to possible differences in outcomes with the type of exercise used. Similarly, patients with BC undergoing different treatments were pooled in the same analysis, this might cause changes in the results. In addition, some prior studies used different control groups [45] or had low statistical power owing to smaller number of participants or shorter durations of follow-up. Moreover, some prior studies evaluated HRQOL and fatigue using different questionnaires and scales which may have led to some reporting bias in their methodology [9].

Overall, our results showed that exercise improved CRF in patients with BC assessed with cycle ergometer. However, stratification by type of exercise yielded interesting findings whereby two different exercise techniques (treadmill versus cycle ergometer) yielded conflicting results for our exercise subgroups (aerobic, resistance or combined). Aerobic exercise training improved CRF by cycle ergometer while combined aerobic and resistance training did not yield any significant improvement. However, aerobic training yielded a non-significant result for CRF using the treadmill ergometer while combined aerobic and resistance training showed marked improvement in CRF. These contradictory findings using the treadmill versus cycle ergometer can possibly indicate some heterogeneity and methodological bias in assessing the maximal oxygen uptake (VO_{max} , key indicator of functional performance [46], since low VO_{max} indicates higher risk of mortality in advanced stages of BC [47]) using the two techniques. While both cycle and treadmill ergometer are known tools for effective assessment of CRF, it should be noted that since they focus on assessing VO_{max} , they are more likely a better choice for assessing aerobic training compared with resistance training. In addition, there is only one study for combined exercise training and no study for resistance training in specific to assess CRF. Hence, the results of combined training can possibly be ignored for this outcome. Nonetheless, the contradictory findings for CRF with aerobic training using cycle ergometer versus treadmill ergometer are important to consider and may suggest that aerobic training using cycle ergometer is more likely to benefit patients with BC undergoing treatment or post-treatment compared with treadmill ergometer.

HRQOL is an important parameter to be evaluated in patients with BC. Our results showed improvement in HROOL overall. However, the results varied with the different types of scales used to assess HRQOL, namely FACT-B and EORTC QLQ-C30 scales. HRQOL assessment using FACT-B scale [48] demonstrated marked improvements across all exercise subgroups (aerobic, resistance and combined). Additionally, there was also evidence of HRQOL improvement with Baduanjin exercise, but more data is needed to confirm this since this result is based on one study only. However, these findings are based on direct post-intervention data from the included studies and does not account for mean change from baseline QOL status. Our pooled analysis of mean change from baseline data including only two studies showed a trend towards improvement in HRQOL but the results were not significant. Given that mean change from baseline is a more accurate way of assessing HRQOL, future studies need to assess HRQOL by taking the baseline status into account. Moreover, details of both baseline and post-intervention result should be provided in the trials. On the other hand, assessment of HRQOL by the EORTC QLQ-C30 scale [49] demonstrated little or no improvements with exercise in patients with BC. Stratification by exercise type suggested improved HRQOL with the combined exercise regimen only. Although exercise has shown improved HRQOL in patients with BC as suggested by our analysis and previous research [8], more studies with emphasis on strengths and weaknesses of assessment scales, and accountability of baseline QOL status should be considered for future research.

Exercise in patients with BC led to significant improvements in physical function assessed by 6-MWT. This is important since worsening of physical function reduces the risk of survival post-treatment [50]. In addition, evidence suggests that exercise provides protection against physical damage such as decreased muscle mass, muscle strength and joint mobility occurring in patients with BC post treatment [51]. However, our analysis presented non-significant improvements in muscle strength with exercise. Furthermore, cancer-related fatigue also affects physical function resulting from various factors including psychological, behavioral and biological, and is one of the most widely reported symptoms in patients with BC [52]. Fatigue assessed by MFI-20 and the revised piper fatigue scale showed little or no difference on patients with BC undergoing exercise regimen, although Thorsten el al [26]. and a meta-analysis in 2016 had shown significant improvement in fatigue in patients with BC undergoing exercise [9]. In future, research should be conducted to assess fatigue-related symptoms in patients with BC, since it can even prove to be fatal in patients with BC undergoing treatment or post-treatment.

Our findings summarize the available trial-level evidence and lay the basis for future research, with the pooled results raising multiple questions which need to be addressed so that clinicians can provide the best possible advice to patients with BC to help alleviate their symptoms. Although exercise can potentially improve HRQOL and physical function, it does not yield any significant benefits over fatigue-related symptoms, and the effects on CRF remain questionable. In future, RCTs should be conducted to evaluate the effects of exercise on CRF and fatigue-related symptoms in patients with BC undergoing treatment or post treatment. In addition, trialists should focus on exploring different types of exercises individually to evaluate which form of exercise is more beneficial for the patients. Although combined exercise seems to reap more beneficial effects than aerobic or resistance training alone, there is a dearth of evidence regarding its effectiveness in patients with BC, which should be evaluated further. Moreover, clinicians should scrupulously evaluate the short-comings of different exercise techniques and assessment scales, and uniformity must be ensured in the upcoming trials with respect to their methodological aspect of evaluating and monitoring the progress with exercise intervention.

The present meta-analysis has some limitations. First, direct post-intervention data was analysed because of lack of availability of data for mean change from baseline. This may have impaired our results as some patients may have had improved physical fitness at baseline. Second, various treatments were utilized along with some included studies assessed outcomes during treatment while others assessed outcomes after treatment which may have led to difference in results owing to treatment status. Third, not all exercise trials were supervised which can cause bias due to deviations from intended exercise. Fourth, long term effects such as adverse events were not evaluated which might limit any definitive conclusion. Fifth, the nature of self-reported questionnaires can lead to response bias. Sixth, significant heterogeneity was reported in analysis of HRQOL and CRF by treadmill ergometer particularly in aerobic exercise intervention which can be attributed to absence of studies, short duration of trials, low statistical power resulted from sample size and various methodologies of aerobic exercise regimen. Furthermore, our study used outcome measures for cancer-related fatigue with varying reliability due to data availability constraints. We relied on handheld dynamometry as a surrogate measure for whole-body muscle strength, and the 6-minute walk test to assess physical functionality as provided by the included studies, despite the availability of more specific assessment tools. These outcomes assessment might be considered unreliable and poorly supported by available psychometric data which can impair our findings. Finally, this is a study-level metaanalysis since individual patient data were not available.

Conclusion

Exercise significantly improves the HRQOL, CRF and physical function in patients with BC during and after treatment. While the effects on HRQOL are consistent with all types of exercise namely aerobic, resistance or combined, the effects on CRF assessed by cycle and treadmill ergometer remain contradictory. Unfortunately, exercise failed to improve any fatigue-related symptoms and muscle strength. Although combined exercise training seems more likely to benefit patients with BC, there is limited evidence to make any confirmatory remarks in this regard. Well-powered RCTs with longer follow-up durations are needed to confirm our findings and resolve the conflicting findings related to exercise and healthrelated outcomes in this high-risk population.

Abbreviations

BC	Breast cancer
RCT	Randomized control trials
QOL	Quality of life
CRF	Cardiorespiratory fitness
HTQOL	Health related quality of life
MD	Mean difference
CI	Confidence interval
SD	Standard deviation
ACSM	American College of Sports Medicine
DOX	Doxorubicin

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40959-024-00235-z.

Supplementary Material 1

Acknowledgements

Not applicable.

Author contributions

NY, AA and MK contributed to conception and design of the manuscript. Analysis and interpretation of the data were conducted by ZW, MS and SFQ. All authors contributed to the drafting of the manuscripts. SU, MS and FM critically revised it for important intellectual content. All authors gave final approval of the manuscript submitted.

Funding

Not applicable.

Data availability

All data generated or analysed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

Ethics approval was not required for our paper since the data used was publicly available.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Division of Cardiology, Banner University Medical Center, University of Arizona, Phoenix, AZ, USA ²Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan

Received: 7 October 2023 / Accepted: 3 May 2024

Published online: 18 June 2024

References

- Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. https://doi.org/10.1016/j.breast.2022.08.010.
- Graf C, Wessely N. Physical activity in the Prevention and Therapy of breast Cancer. Breast care (Basel Switzerland). 2010;5(6):389–94. https://doi. org/10.1159/000322650.
- Justin C, Brown TB, Huedo-Medina LS, Pescatello SM, Pescatello RA, Ferrer, Blair T. Johnson; efficacy of Exercise interventions in modulating Cancerrelated fatigue among Adult Cancer survivors: a Meta-analysis. Cancer Epidemiol Biomarkers Prev 1 January. 2011;20(1):123–33. https://doi. org/10.1158/1055-9965.EPI-10-0988.
- Ruiz-Casado A, Alvarez-Bustos A, De Pedro CG, Méndez-Otero M, Romero-Elías M. Cancer-related fatigue in breast Cancer survivors: a review. Clin Breast Cancer. 2021;21(1):10–25. https://doi.org/10.1016/j.clbc.2020.07.011.
- Lovelace DL, McDaniel LR, Golden D. Long-term effects of breast cancer surgery, treatment, and survivor care. J Midwifery Women's Health. 2019;64(6):713–24. https://doi.org/10.1111/jmwh.13012.
- Dickinson JM, D'Lugos AC, Mahmood TN, Ormsby JC, Salvo L, Dedmon WL, Patel SH, Katsma MS, Mookadam F, Gonzales RJ, Hale TM, Carroll CC, Angadi SS. Exercise protects skeletal muscle during chronic Doxorubicin Administration. Med Sci Sports Exerc. 2017;49(12):2394–403. https://doi.org/10.1249/ MSS.000000000001395.
- Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 2015;15:77. https://doi. org/10.1186/s12885-015-1069-4.
- McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. Volume 175. CMAJ: Canadian Medical Association

journal = journal de l'Association medicale canadienne; 2006. pp. 34–41. 1https://doi.org/10.1503/cmaj.051073.

- Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2016;9(9):CD005001. https://doi.org/10.1002/14651858.CD005001.pub3.
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., ? Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed.), 372, n71. https://doi.org/10.1136/bmj.n71
- Lorenzetti DL, Ghali WA. Reference management software for systematic reviews and meta-analyses: an exploration of usage and usability. BMC Med Res Methodol. 2013;13:1–5.
- 12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
- Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.
- Segal R, Evans W, Johnson D, Smith J, Colletta S, Gayton J, Woodard S, Wells G, Reid R. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol. 2001;19(3):657–65.
- 15. Drouin J. Aerobic exercise training effects on physical function, fatigue and mood, immune status, and oxidative stress in subjects undergoing radiation treatment for breast cancer. Wayne State University; 2002.
- Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003;21(9):1660–8.
- 17. Battaglini CL. A randomized study on the effects of a prescribed exercise intervention on lean mass and fatigue changes in breast cancer patients during treatment. University of Northern Colorado; 2007.
- Mock V, Frangakis C, Davidson NE, Ropka ME, Pickett M, Poniatowski B, Stewart KJ, Cameron L, Zawacki K, Podewils LJ, Cohen G. Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psycho-Oncology: J Psychol Social Behav Dimensions Cancer. 2005;14(6):464–77.
- Campbell A, Mutrie N, White F, McGuire F, Kearney N. A pilot study of a supervised group exercise programme as a rehabilitation treatment for women with breast cancer receiving adjuvant treatment. Eur J Oncol Nurs. 2005;9(1):56–63.
- Saarto T, Penttinen HM, Sievänen H, Kellokumpu-Lehtinen PL, Hakamies-Blomqvist L, Nikander R, Huovinen R, Luoto R, Kautiainen H, Järvenpää S, Idman I. Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors. Anticancer Res. 2012;32(9):3875–84.
- Schmidt T, Weisser B, Jonat W, Baumann FT, Mundhenke C. Gentle strength training in rehabilitation of breast cancer patients compared to conventional therapy. Anticancer Res. 2012;32(8):3229–33.
- 22. Rogers LQ, Courneya KS, Anton PM, Hopkins-Price P, Verhulst S, Vicari SK, Robbs RS, Mocharnuk R, McAuley E. Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2015;149:109–19.
- Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int J Cancer. 2015;137(2):471–80.
- Steindorf K, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Habermann N, Beckhove P, Owen R, Debus J, Wiskemann J, Potthoff K. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol. 2014;25(11):2237–43.
- 25. Murtezani A, Ibraimi Z, Bakalli A, Krasniqi S, Disha ED, Kurtishi I. The effect of aerobic exercise on quality of life among breast cancer survivors: a randomized controlled trial. J Cancer Res Ther. 2014;10(3):658–64.
- Schmidt T, Weisser B, Duerkop J, Jonat W, Van Mackelenbergh M, Roecken C, Mundhenke C. Comparing endurance and resistance training with standard care during chemotherapy for patients with primary breast cancer. Anticancer Res. 2015;35(10):5623–9.
- 27. Campbell KL, Kam JW, Neil-Sztramko SE, Liu Ambrose T, Handy TC, Lim HJ, Hayden S, Hsu L, Kirkham AA, Gotay CC, McKenzie DC. Effect of aerobic

exercise on cancer-associated cognitive impairment: a proof-of-concept RCT. Psycho-oncology. 2018;27(1):53–60.

- Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, Stewart C, Buchanan TA, Spicer D, Tripathy D, Bernstein L. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res. 2018;20(1):1–0.
- Cešeiko R, Eglitis J, Srebnijs A, Timofejevs M, Purmalis E, Erts R, Větra A, Tomsone S. The impact of maximal strength training on quality of life among women with breast cancer undergoing treatment. Exp Oncol. 2019;41(2):166–72.
- Northey JM, Pumpa KL, Quinlan C, Ikin A, Toohey K, Smee DJ, Rattray B. Cognition in breast cancer survivors: a pilot study of interval and continuous exercise. J Sci Med Sport. 2019;22(5):580–5.
- Scott JM, Thomas SM, Peppercorn JM, Herndon JE, Douglas PS, Khouri MG, Dang CT, Yu AF, Catalina D, Ciolino C, Capaci C. Effects of exercise therapy dosing schedule on impaired cardiorespiratory fitness in patients with primary breast cancer: a randomized controlled trial. Circulation. 2020;141(7):560–70.
- Ruiz-Vozmediano J, Löhnchen S, Jurado L, Recio R, Rodríguez-Carrillo A, López M, Mustieles V, Expósito M, Arroyo-Morales M, Fernández MF. Influence of a multidisciplinary program of diet, exercise, and mindfulness on the quality of life of stage IIA-IIB breast cancer survivors. Integr Cancer Ther. 2020;19:1534735420924757.
- Lee K, Norris MK, Wang E, Dieli-Conwright CM. Effect of high-intensity interval training on patient-reported outcomes and physical function in women with breast cancer receiving anthracycline-based chemotherapy. Support Care Cancer. 2021;29(11):6863–70.
- Eyigör S, Apaydin S, Yesil H, Tanıgor G, Bicakli DH. Effects of yoga on Phase Angle and Quality of Life in patients with breast Cancer: a Randomized, Single-Blind, controlled trial. Complement Med Res. 2021;28(6):523–32.
- Heiman J, Onerup A, Bock D, Haglind E, Olofsson Bagge R. The effect of nonsupervised physical activity before and after breast cancer surgery on quality of life: results from a randomized controlled trial (PhysSURG-B). Scand J Surg. 2022;111(4):75–82.
- 36. Lin Y, Wu C, He C, Yan J, Chen Y, Gao L, Liu R, Cao B. Effectiveness of three exercise programs and intensive follow-up in improving quality of life, pain, and lymphedema among breast cancer survivors: a randomized, controlled 6-month trial. Support Care Cancer. 2023;31(1):1–1.
- Ochi E, Tsuji K, Narisawa T, Shimizu Y, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N, Matsuoka Y. Cardiorespiratory fitness in breast cancer survivors: a randomised controlled trial of home-based smartphone supported high intensity interval training. BMJ Supportive Palliat Care. 2022;12(1):33–7.
- Wei X, Yuan R, Yang J, Zheng W, Jin Y, Wang M, Jiang J, Wu C, Li K. Effects of Baduanjin exercise on cognitive function and cancer-related symptoms in women with breast cancer receiving chemotherapy: a randomized controlled trial. Support Care Cancer. 2022;30(7):6079–91.
- Lee KJ, An KO. Impact of high-intensity circuit resistance exercise on physical fitness, inflammation, and immune cells in female breast cancer survivors: a randomized control trial. Int J Environ Res Public Health. 2022;19(9):5463.
- Chung WP, Yang HL, Hsu YT, Hung CH, Liu PY, Liu YW, Chan SH, Tsai KL. Realtime exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: a randomized controlled trial. Annals Phys Rehabilitation Med. 2022;65(2):101485.

- Charati FG, Shojaee L, Haghighat S, Esmaeili R, Madani Z, Charati JY, Hosseini SH, Shafipour V. Motor exercises effect on improving shoulders functioning, functional ability, quality of life, depression and anxiety for women with breast Cancer. Clin Breast Cancer. 2022;22(7):666–73.
- Ax AK, Johansson B, Lyth J, Nordin K, Börjeson S. Short-and long-term effect of high versus low-to-moderate intensity exercise to optimise health-related quality of life after oncological treatment—results from the Phys-Can project. Support Care Cancer. 2022;30(7):5949–63.
- Kokkonen K, Kellokumpu-Lehtinen PL, Kankaanpää M, Nikander R, Penttinen HM, Utriainen M, Vehmanen L, Huovinen R, Kautiainen H, Blomqvist C, Saarto T. Factors predicting long-term physical activity of breast cancer survivors. 5-year-follow-up of the BREX exercise intervention study. Acta Oncol. 2022;61(10):1200–8.
- Kang JJ, Lee H, Park BH, Song YK, Park SE, Kim R, Lee KA. Efficacy of a 4-Week nurse-led Exercise Rehabilitation Program in improving the quality of life in women receiving a Post-mastectomy Reconstruction using the Motiva ErgonomixTM Round SilkSurface. Int J Environ Res Public Health. 2022;20(1):16.
- Fong DY, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Leung SS, Cerin E, Chan WY, Leung IP, Lam SH, Taylor AJ. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 2012;344:e70.
- Strasser B, Burtscher M. Survival of the fittest: VO2max, a key predictor of longevity? Front Bioscience-Landmark. 2018;23(8):1505–16.
- 47. Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Association. 2014;3(1):e000432.
- Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JC, Kaasa S. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: J Natl Cancer Inst. 1993;85(5):365–76.
- Lee K, Norris MK, Wang E, Dieli-Conwright CM. Effect of high-intensity interval training on patient-reported outcomes and physical function in women with breast cancer receiving anthracycline-based chemotherapy. Supportive care cancer: Official J Multinational Association Supportive Care Cancer. 2021;29(11):6863–70. https://doi.org/10.1007/s00520-021-06294-7.
- Montaño-Rojas LS, Romero-Pérez EM, Medina-Pérez C, Reguera-García MM, de Paz JA. Resistance training in breast cancer survivors: a systematic review of exercise programs. Int J Environ Res Public Health. 2020;17(18):6511.
- Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nature reviews. Clin Oncol. 2014;11(10):597–609. https://doi.org/10.1038/ nrclinonc.2014.127.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.